OCUL Shares Outstanding History



Below is a table of the OCUL shares outstanding history going back to 7/25/2014:

Date OCUL Shares Outstanding
7/25/201420.57M
8/25/201421.32M
11/3/201421.32M
3/13/201521.42M
5/3/201521.44M
7/31/201524.72M
10/31/201524.73M
3/1/201624.75M
5/1/201624.77M
8/1/201624.82M
11/1/201624.88M
3/1/201728.76M
5/1/201729.03M
8/1/201729.06M
11/1/201729.44M
3/1/201837.28M
5/1/201837.28M
8/1/201838.59M
11/1/201841.10M
3/1/201942.84M
5/1/201942.84M
8/5/201947.20M
7/26/201936.84M
11/7/201948.08M
3/2/202052.58M
5/1/202053.36M
8/1/202062.96M
11/1/202071.39M
3/1/202176.07M
5/1/202176.29M
8/4/202176.58M
11/3/202176.61M
2/24/202276.75M
5/6/202276.76M
8/5/202276.97M
11/4/202277.01M
5/4/202377.52M
8/3/202379.38M
11/3/202379.42M
3/6/2024148.63M
5/3/2024154.89M
8/2/2024155.92M
11/11/2024157.22M

Also see: OCUL Market Cap History
OCUL YTD Return
OCUL Historical Shares Outstanding:
+21.81% CAGR
OCUL Historical Shares Outstanding: +21.81% CAGR

Mouse over chart for data details
7/25/2014 ...11/11/2024
Ocular Therapeutix, Inc. is a biopharmaceutical company engaged in the development and commercialization therapies for eye conditions, including wet age-related macular degeneration (wet AMD), diabetic retinopathy and other ocular diseases. Co.'s commercial product, DEXTENZA, treats ocular inflammation and pain following eye surgery and ocular itching due to allergic conjunctivitis. Co. is also developing OTX-DED for short-term dry eye disease treatment and OTX-CSI for chronic dry eye disease management. It is conducting a Phase III trial for AXPAXLI to treat wet AMD and are also advancing PAXTRAVA in Phase III clinical development for primary open-angle glaucoma or ocular hypertension. We show 43 historical shares outstanding datapoints in our coverage of OCUL's shares outstanding history.

Understanding the changing numbers of OCUL shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like OCUL versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching OCUL by allowing them to research OCUL shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree OCUL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Ocular Therapeutix (OCUL) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

OCUP Shares Outstanding History
OCX Shares Outstanding History
ODT Shares Outstanding History
OFIX Shares Outstanding History
OGN Shares Outstanding History
OHRP Shares Outstanding History
OKUR Shares Outstanding History
OLMA Shares Outstanding History
OM Shares Outstanding History
OMED Shares Outstanding History
More Healthcare companies »

 

OCUL Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2025, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.3%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.3%.